Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435838 | 1.00 | KDM4E (0.65) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL12807977 | 1.00 | KDM4E (0.65) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Cysteamine SCHEMBL20768363 | 0.92 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL18098148 | 0.92 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL931282 | 0.92 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Cysteine SCHEMBL23539583 | 0.87 | NFKB1 (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL13295204 | 0.86 | KDM4E (0.71) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9962914 | 0.86 | KDM4E (0.71) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL26430637 | 0.86 | KDM4E (0.71) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL10070143 | 0.83 | KDM4E (0.50) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083688-A1 | N-Acetylcysteine Amide Tablets Inhibit Reduction in Vision in Patients with Usher Syndrome Associated Retinitis Pigmentosa | NACUITY PHARMACEUTICALS INC (US) | 2026-03-26 | — | — | US | claimed |
| US-12578341-B2 | Iterative fluorescence imaging | Universität Zürich (CH) | 2026-03-17 | — | — | US | claimed |
| US-12472157-B2 | Treatment of retinitis pigmentosa with n-acetylcysteine amide | NACUITY PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4626414-A1 | SYNERGISTIC COMBINATIONS OF REGULATED NECROSIS INHIBITORS WITH N-ACETYLCYSTEINE | Seabelife (FR) | 2025-10-08 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250235416-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | NACUITY PHARMACEUTICALS, INC. | 2025-07-24 | — | — | US | claimed |
| CN-119020291-B | Buffer solution for tissue separation and preservation, application thereof and method for culturing tumor organoids | 山东伯桢生物科技有限公司 | 2025-05-20 | — | — | CN | claimed |
| EP-4551203-A1 | OPHTHALMIC IMPLANT | NaCuity Pharmaceuticals, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119894506-A | Ophthalmic implant | 纳崔泰制药有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119868324-A | Application of N-acetylcysteine amide as preparation for relieving or removing pesticide poisoning of bees | 华南农业大学 | 2025-04-25 | — | — | CN | claimed |
| WO-2006020727-A2 | METHODS FOR TREATING CNS DISORDERS BY ADMINISTRATION OF AGENTS TO THE NASAL CAVITY | HEALTHPARTNERS RESEARCH FOUNDATION (US) | 2006-02-23 | — | — | WO | claimed |
| EP-1539023-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) | 2005-06-15 | — | — | EP | claimed |
| WO-2004012652-A9 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2004-06-17 | — | — | WO | claimed |
| WO-2004012652-A2 | TREATMENT OF MULTIPLE SCLEROSIS WITH BRAIN TARGETED ANTI OXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | claimed |
| US-20030229141-A1 | N-acetyl cysteine and its topical use | YU RUEY J (US) | 2003-12-11 | — | — | US | claimed |
| EP-1242070-A4 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RES DEV CO (IL) | 2003-05-28 | — | — | EP | claimed |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-05-01 | — | — | US | claimed |
| EP-1242070-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-25 | — | — | EP | claimed |
| US-6369106-B1 | SULFHYDRYL CONTAINING COMPOUND AS ANTIOXIDANT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-04-09 | — | — | US | claimed |
| WO-2001047469-A2 | TREATMENT OF ISCHEMIC BRAIN INJURIES WITH BRAIN TARGETTED ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-07-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472157-B2 | Treatment of retinitis pigmentosa with n-acetylcysteine amide | ALDH1A2, NQO1, CRAT | KDM4E 3824/4885MAPT 2158/4885THRB 2125/4885 |
| US-20250235416-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | NACA, NAA15, SLC33A1 | KDM4E 4603/4885MAPT 647/4885THRB 2405/4885 |
| US-12578341-B2 | Iterative fluorescence imaging | FGB, CLTB, CD44 | KDM4E 3013/4885MAPT 2415/4885THRB 2327/4885 |
| US-20030083266-A1 | Treatment of ischemic brain injuries with brain targeted antioxidant compounds | GPX4, GPX1, TXN2 | KDM4E 4595/4885MAPT 1162/4885THRB 2735/4885 |
| US-20260083688-A1 | N-Acetylcysteine Amide Tablets Inhibit Reduction in Vision in Patients with Usher Syndrome Associated Retinitis Pigmentosa | ALDH1A2, USP24, USP25 | KDM4E 4655/4885MAPT 1887/4885THRB 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.